Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,831,251
  • Shares Outstanding, K 57,424
  • Annual Sales, $ 714,730 K
  • Annual Income, $ 145,490 K
  • EBIT $ 195 M
  • EBITDA $ 218 M
  • 60-Month Beta 0.87
  • Price/Sales 2.61
  • Price/Cash Flow 11.02
  • Price/Book 2.59

Options Overview Details

View History
  • Implied Volatility 66.46% ( +3.76%)
  • Historical Volatility 33.30%
  • IV Percentile 59%
  • IV Rank 59.07%
  • IV High 85.78% on 08/02/24
  • IV Low 38.57% on 01/21/25
  • Put/Call Vol Ratio 11.56
  • Today's Volume 113
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 4,023
  • Open Int (30-Day) 3,612

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.78
  • Number of Estimates 4
  • High Estimate 0.93
  • Low Estimate 0.43
  • Prior Year 0.20
  • Growth Rate Est. (year over year) +290.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.55 +1.08%
on 06/20/25
36.47 -12.56%
on 06/10/25
-3.73 (-10.47%)
since 05/20/25
3-Month
26.47 +20.48%
on 04/09/25
36.47 -12.56%
on 06/10/25
-3.01 (-8.62%)
since 03/20/25
52-Week
26.47 +20.48%
on 04/09/25
41.61 -23.36%
on 10/29/24
+3.08 (+10.69%)
since 06/20/24

Most Recent Stories

More News
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment.Jazz Pharmaceuticals markets multiple neuroscience...

JAZZ : 107.51 (-0.67%)
HRMY : 31.89 (-1.82%)
HRMY Down 10.8% in Six Months: How Should You Play the Stock?

Shares of Harmony Biosciences HRMY have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe.The stock...

JAZZ : 107.51 (-0.67%)
HRMY : 31.89 (-1.82%)
AXSM : 100.69 (-2.14%)
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript

HRMY earnings call for the period ending December 31, 2024.

HRMY : 31.89 (-1.82%)
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth

Axsome Therapeutics AXSM incurred an adjusted loss of 96 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of...

JAZZ : 107.51 (-0.67%)
HRMY : 31.89 (-1.82%)
PCRX : 24.23 (+0.33%)
AXSM : 100.69 (-2.14%)
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals AGIO incurred a loss of $1.74 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.73. In the year-ago quarter, the company had reported...

AGIO : 34.41 (-3.07%)
HRMY : 31.89 (-1.82%)
PCRX : 24.23 (+0.33%)
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up

Alkermes plc ALKS reported adjusted earnings from continuing operations of $1.04 per share for fourth-quarter 2024, which beat the Zacks Consensus Estimate of 81 cents. The company had reported adjusted...

HRMY : 31.89 (-1.82%)
PCRX : 24.23 (+0.33%)
ALKS : 29.09 (-0.82%)
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...

BEAM : 16.76 (-1.35%)
VYGR : 2.97 (-2.30%)
CSTL : 18.52 (-2.06%)
HRMY : 31.89 (-1.82%)
Zacks.com featured highlights include Harmony Biosciences, Ingevity, Gulfport Energy and Pitney Bowes

For Immediate ReleaseChicago, IL – January 24, 2025 – Stocks in this week’s article are — Harmony Biosciences HRMY, Ingevity Corp. NGVT, Gulfport Energy GPOR and Pitney Bowes PBI.4 High Earnings...

NGVT : 41.31 (-0.17%)
PBI : 10.24 (-1.44%)
HRMY : 31.89 (-1.82%)
GPOR : 206.57 (+0.52%)
4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency

The favorable December inflation reading has eased concerns about the Federal Reserve’s ability to justify rate cuts in 2025. Adding to the positive sentiment is the strong start to the fourth-quarter...

NGVT : 41.31 (-0.17%)
PBI : 10.24 (-1.44%)
HRMY : 31.89 (-1.82%)
GPOR : 206.57 (+0.52%)
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript

HRMY earnings call for the period ending September 30, 2024.

HRMY : 31.89 (-1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 33.53
2nd Resistance Point 33.06
1st Resistance Point 32.48
Last Price 31.89
1st Support Level 31.43
2nd Support Level 30.96
3rd Support Level 30.38

See More

52-Week High 41.61
Fibonacci 61.8% 35.83
Fibonacci 50% 34.04
Fibonacci 38.2% 32.25
Last Price 31.89
52-Week Low 26.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar